Prostatic Artery Embolization for the Treatment of Symptomatic Benign Prostatic Hyperplasia (BPH)
Prostatic Artery Embolization for the Treatment of Symptomatic Benign Prostatic Hyperplasia (BPH)
This is a single center, prospective, investigational study to evaluate the safety and
 efficacy of prostatic artery embolization (PAE) for the treatment of moderate to severe lower
 urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH). Embolization will be
 performed with LC Bead LUMI particles using a balloon occlusion microcatheter or standard
 microcatheter.
Inclusion Criteria:

 -  Age ≥ 45 years and ≤ 85 years old

 -  Prostate volume ≥ 40 mL and ≤ 300 mL

 -  Diagnosis of BPH with moderate to severe lower urinary tract symptoms (LUTS)

 -  Refractory or intolerant to medical management

 -  Ineligibility for or refusal of surgical management

 -  No evidence of prostate cancer

 Exclusion Criteria:

 -  History of pelvic cancer

 -  Neurogenic bladder disorder

 -  Bladder diverticula greater than 5 cm or bladder stones

 -  Acute urinary retention with Foley catheter dependence

 -  Active urinary tract infection, interstitial cystitis, or prostatitis within the last
 3 months

 -  Prior surgical prostate intervention

 -  Active participation in another clinical trial